pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·3h ago·1 min read
save

Trump administration pulls nearly $1 billion from HHS programs for immigrants and diversity

Sep 28, 2026·read at STAT ↗RegulatoryNegative

The White House announced a reversal of almost $1 billion in spending that Congress had previously approved for the Department of Health and Human Services. The reduction was made late on Friday night and is being described as a contested use of executive authority.

The cut targets several HHS initiatives that focus on services for immigrant populations and programs aimed at promoting diversity within the health system. By withdrawing the funds, the administration is effectively scaling back resources that were intended to support these groups.

Industry observers note that the funding pull could affect a range of health‑related activities, from community health outreach to research grants that address health disparities. The reduction may also influence how pharmaceutical companies engage with underserved communities and could alter the landscape for public‑private collaborations in these areas.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Trump uses ‘contested’ power to cut more funding to HHS”

read at STAT ↗
1,351 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO2Ultragenyx Pharmaceutical Inc.2Novo Nordisk IncRISING
drugs
MIFEPRISTONE5Obesity
topics
CRISPR/Cas95GLP-1 receptor2Rare Disease2CardiologyObesityVaccine

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Aug 28STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT
  • Sep 15Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with AscendisFierce Biotech
  • Sep 14Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrandBioSpace
  • Aug 28Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist MounjaroBioSpace